joris

Portfolio overview

Predictions about biotech companies, written down before the news arrives and then locked. We analyse one program at a time. A program is one drug for one disease, not the whole company. Each program has one big event that will come out as a clear yes or no (a "binary catalyst"), such as a trial result. We predict two things separately: the outcome (does the trial or the regulator say yes?) and the stock direction (does the share price go up or down around the event?). Unfamiliar words are explained in the glossary.

Data as of 2026-10-17

Companies

22

stock ticker symbols covered

Programs analysed

24

24 passed the data-coverage check

Predictions locked

24

outcome and stock

Settled

11

13 awaiting the result

Next catalyst

2026-08-26

earliest confirmed readout

Catalyst timeline

When each analysed program is expected to report its result

Confirmed readout window (the period in which the result is expected, from a company statement or similar source) Placeholder: a rough period estimate from BPIQ (a biotech data service), not a date the company has given
Q3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027LGVNLGVN Laromestrocel (Lomecel-B): confirmed readout window 2026-08-12 to 2026-10-31, most likely date 2026-08-26VALNVALN Shigella4V2 (S4V2): confirmed readout window 2026-08-13 to 2026-12-31, most likely date 2026-09-30MNOVMNOV MN-001 (tipelukast): confirmed readout window 2026-08-26 to 2026-10-31, most likely date 2026-09-24ARCTARCT ARCT-810 (LUNAR-OTC): confirmed readout window 2026-09-01 to 2026-11-30, most likely date 2026-09-25CNTBCNTB Rademikibart (CBP-201): confirmed readout window 2026-09-01 to 2026-10-31, most likely date 2026-09-15CNTBCNTB Rademikibart (CBP-201): confirmed readout window 2026-09-01 to 2026-10-31, most likely date 2026-09-21EVMNEVMN EVO756 (oral MRGPRX2 antagonist): confirmed readout window 2026-09-01 to 2026-09-30, most likely date 2026-09-15IRONIRON DISC-3405 (formerly MWTX-003): confirmed readout window 2026-09-01 to 2026-10-31, most likely date 2026-09-25RARERARE GTX-102 (apazunersen): confirmed readout window 2026-09-01 to 2026-11-10, most likely date 2026-10-15TYRATYRA dabogratinib (TYRA-300): confirmed readout window 2026-09-01 to 2026-10-31, most likely date 2026-09-15CUECUE CUE-221 (formerly Ascendant-221, formerly UB-221) - humanised anti-IgE IgG1 monoclonal antibody: confirmed readout window 2026-09-15 to 2026-12-15, most likely date 2026-09-30TLSATLSA intranasal foralumab (TZLS-401 / NI-0401): confirmed readout window 2026-09-15 to 2026-11-30, most likely date 2026-10-21CGEMCGEM Zipalertinib (CLN-081 / TAS-6417): confirmed readout window 2026-10-01 to 2027-03-31, most likely date 2026-11-30DWTXDWTX Halneuron (purified tetrodotoxin): confirmed readout window 2026-10-01 to 2026-12-31, most likely date 2026-11-15GNLXGNLX Olvi-Vec (olvimulogene nanivacirepvec), also known as GL-ONC1 and GLV-1h68, an engineered oncolytic vaccinia virus, given intraperitoneally and followed by platinum-doublet chemotherapy plus bevacizumab: confirmed readout window 2026-10-01 to 2027-04-30, most likely date 2026-12-15IVAIVA lanifibranor (IVA337): confirmed readout window 2026-10-01 to 2026-12-31, most likely date 2026-11-15RAPPRAPP RAP-219: confirmed readout window 2026-10-01 to 2026-11-30, most likely date 2026-10-22IMMPIMMP Eftilagimod alfa (efti, IMP321) with pembrolizumab and radiotherapy: confirmed readout window 2026-10-19 to 2026-10-19, most likely date 2026-10-19CMPXCMPX Tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody: confirmed readout window 2026-10-23 to 2026-10-27, most likely date 2026-10-24ABOSABOS sabirnetug (ACU193): confirmed readout window 2026-11-15 to 2027-01-31, most likely date 2026-12-15IMUXIMUX vidofludimus calcium (IMU-838): confirmed readout window 2026-12-01 to 2027-03-31, most likely date 2026-12-15OLMAOLMA palazestrant (OP-1250): confirmed readout window 2027-01-01 to 2027-06-30, most likely date 2027-02-15RARERARE DTX301 (avalotcagene ontaparvovec): confirmed readout window 2027-01-01 to 2027-09-30, most likely date 2027-06-15ZNTLZNTL azenosertib (ZN-c3): confirmed readout window 2027-01-01 to 2027-06-30, most likely date 2027-04-15

24 of 24 analysed programshave a confirmed readout window.

Table view (the same information as the chart, as text)
ProgramTimingSource
LGVN — Laromestrocel (Lomecel-B)2026-08-12 to 2026-10-31Confirmed
VALN — Shigella4V2 (S4V2)2026-08-13 to 2026-12-31Confirmed
MNOV — MN-001 (tipelukast)2026-08-26 to 2026-10-31Confirmed
ARCT — ARCT-810 (LUNAR-OTC)2026-09-01 to 2026-11-30Confirmed
CNTB — Rademikibart (CBP-201)2026-09-01 to 2026-10-31Confirmed
CNTB — Rademikibart (CBP-201)2026-09-01 to 2026-10-31Confirmed
EVMN — EVO756 (oral MRGPRX2 antagonist)2026-09-01 to 2026-09-30Confirmed
IRON — DISC-3405 (formerly MWTX-003)2026-09-01 to 2026-10-31Confirmed
RARE — GTX-102 (apazunersen)2026-09-01 to 2026-11-10Confirmed
TYRA — dabogratinib (TYRA-300)2026-09-01 to 2026-10-31Confirmed
CUE — CUE-221 (formerly Ascendant-221, formerly UB-221) - humanised anti-IgE IgG1 monoclonal antibody2026-09-15 to 2026-12-15Confirmed
TLSA — intranasal foralumab (TZLS-401 / NI-0401)2026-09-15 to 2026-11-30Confirmed
CGEM — Zipalertinib (CLN-081 / TAS-6417)2026-10-01 to 2027-03-31Confirmed
DWTX — Halneuron (purified tetrodotoxin)2026-10-01 to 2026-12-31Confirmed
GNLX — Olvi-Vec (olvimulogene nanivacirepvec), also known as GL-ONC1 and GLV-1h68, an engineered oncolytic vaccinia virus, given intraperitoneally and followed by platinum-doublet chemotherapy plus bevacizumab2026-10-01 to 2027-04-30Confirmed
IVA — lanifibranor (IVA337)2026-10-01 to 2026-12-31Confirmed
RAPP — RAP-2192026-10-01 to 2026-11-30Confirmed
IMMP — Eftilagimod alfa (efti, IMP321) with pembrolizumab and radiotherapy2026-10-19 to 2026-10-19Confirmed
CMPX — Tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody2026-10-23 to 2026-10-27Confirmed
ABOS — sabirnetug (ACU193)2026-11-15 to 2027-01-31Confirmed
IMUX — vidofludimus calcium (IMU-838)2026-12-01 to 2027-03-31Confirmed
OLMA — palazestrant (OP-1250)2027-01-01 to 2027-06-30Confirmed
RARE — DTX301 (avalotcagene ontaparvovec)2027-01-01 to 2027-09-30Confirmed
ZNTL — azenosertib (ZN-c3)2027-01-01 to 2027-06-30Confirmed

Programs by company

The chance of a good outcome and the two stock scenarios are worked out separately, each from its own named evidence, so they do not always agree

Program Catalyst Data check Outcome Scenario prices Expected price vs today
LGVN Longeveron Inc 1 analysed program
Laromestrocel (Lomecel-B) Hypoplastic left heart syndrome (HLHS) — adjunct to stage-2 (Glenn) surgical palliation in infants 2026-08-12 → 2026-10-31 confirmed readout window (expected period) Cleared (data check passed)
Miss
30% [20–40]
$0.22–$0.45 $1.20–$2.20
$0.74+0.6% modelled estimate

-17.8% to +19.1% compared with the current price, across our 20–40% range of probabilities. We cannot tell yet whether it is above or below the current price.

VALN Valneva SE 1 analysed program
Shigella4V2 (S4V2) Prevention of shigellosis caused by Shigella sonnei and Shigella flexneri serotypes 2a, 3a and 6 2026-08-13 → 2026-12-31 confirmed readout window (expected period) Cleared (data check passed)
Miss
32% [20–47]
$4.60–$5.15 $5.80–$7.00
$5.36+1.2% modelled estimate

-2.3% to +5.5% compared with the current price, across our 20–47% range of probabilities. We cannot tell yet whether it is above or below the current price.

MNOV MediciNova, Inc. 1 analysed program
MN-001 (tipelukast) Hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) due to type 2 diabetes mellitus (T2DM) 2026-08-26 → 2026-10-31 confirmed readout window (expected period) Cleared (data check passed)
Miss
15% [8–28]
$1.05–$1.50 $1.60–$2.15
$1.37+2.6% modelled estimate

-0.5% to +8.5% compared with the current price, across our 8–28% range of probabilities. We cannot tell yet whether it is above or below the current price.

ARCT Arcturus Therapeutics Holdings Inc. 1 analysed program
ARCT-810 (LUNAR-OTC) Ornithine transcarbamylase (OTC) deficiency 2026-09-01 → 2026-11-30 confirmed readout window (expected period) Cleared (data check passed)
Miss
38% [25–52]
$6.00–$7.20 $9.50–$13.00
$8.37+5.0% modelled estimate

-2.6% to +13.1% compared with the current price, across our 25–52% range of probabilities. We cannot tell yet whether it is above or below the current price.

CNTB Connect Biopharma Holdings Limited 2 analysed programs
Rademikibart (CBP-201) Acute exacerbations of asthma with type 2 inflammation (blood eosinophils >=300 cells/uL), in adults and adolescents aged 12-75 2026-09-01 → 2026-10-31 confirmed readout window (expected period) Cleared (data check passed)
Miss
38% [26–52]
$0.95–$1.60 $3.60–$6.50
$2.71+16.3% modelled estimate

-3.2% to +39.0% compared with the current price, across our 26–52% range of probabilities. We cannot tell yet whether it is above or below the current price.

Rademikibart (CBP-201) Acute exacerbations of COPD with type 2 inflammation (blood eosinophils >=300 cells/uL at the exacerbation), in adults aged 40-80, given as an add-on to standard of care 2026-09-01 → 2026-10-31 confirmed readout window (expected period) Cleared (data check passed)
Miss
30% [20–42]
$1.10–$2.10 $4.00–$7.00
$2.77+8.2% modelled estimate

-7.0% to +26.5% compared with the current price, across our 20–42% range of probabilities. We cannot tell yet whether it is above or below the current price.

EVMN Evommune, Inc. 1 analysed program
EVO756 (oral MRGPRX2 antagonist) Moderate-to-severe atopic dermatitis 2026-09-01 → 2026-09-30 confirmed readout window (expected period) Cleared (data check passed)
Miss
30% [20–45]
$8.50–$11.00 $21.00–$30.00
$14.48+1.6% modelled estimate

-9.5% to +18.2% compared with the current price, across our 20–45% range of probabilities. We cannot tell yet whether it is above or below the current price.

IRON Disc Medicine, Inc. 1 analysed program
DISC-3405 (formerly MWTX-003) Polycythemia vera 2026-09-01 → 2026-10-31 confirmed readout window (expected period) Cleared (data check passed)
Positive
78% [65–87]
$67.00–$74.00 $84.00–$91.00
$83.76+5.3% modelled estimate

+2.6% to +7.3% compared with the current price, across our 65–87% range of probabilities. We cannot tell yet whether it is above or below the current price.

RARE Ultragenyx Pharmaceutical Inc. 2 analysed programs
DTX301 (avalotcagene ontaparvovec) Late-onset ornithine transcarbamylase (OTC) deficiency, age 12 and over 2027-01-01 → 2027-09-30 confirmed readout window (expected period) Cleared (data check passed)
Positive
62% [48–75]
$22.00–$27.00 $27.00–$33.00
$27.91+4.6% modelled estimate

+1.8% to +7.3% compared with the current price, across our 48–75% range of probabilities. We cannot tell yet whether it is above or below the current price.

GTX-102 (apazunersen) Angelman syndrome caused by full maternal UBE3A deletion, ages 4-17 2026-09-01 → 2026-11-10 confirmed readout window (expected period) Cleared (data check passed)
Uncertain
50% [35–65]
$16.00–$21.00 $34.00–$42.00
$28.25+9.4% modelled estimate

-1.9% to +20.7% compared with the current price, across our 35–65% range of probabilities. We cannot tell yet whether it is above or below the current price.

TYRA Tyra Biosciences 1 analysed program
dabogratinib (TYRA-300) Low-grade, intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), FGFR3-altered 2026-09-01 → 2026-10-31 confirmed readout window (expected period) Cleared (data check passed)
Positive
55% [40–68]
$14.00–$20.00 $30.00–$46.00
$28.55+5.9% modelled estimate

-5.8% to +16.0% compared with the current price, across our 40–68% range of probabilities. We cannot tell yet whether it is above or below the current price.

CUE Cue Biopharma, Inc. 1 analysed program
CUE-221 (formerly Ascendant-221, formerly UB-221) - humanised anti-IgE IgG1 monoclonal antibody Chronic spontaneous urticaria (long-lasting hives with no identifiable trigger), in patients inadequately controlled by H1-antihistamines 2026-09-15 → 2026-12-15 confirmed readout window (expected period) Cleared (data check passed)
Positive
72% [58–83]
$9.00–$16.00 $24.00–$46.00
$28.70+10.0% modelled estimate

-2.1% to +19.4% compared with the current price, across our 58–83% range of probabilities. We cannot tell yet whether it is above or below the current price.

TLSA Tiziana Life Sciences 1 analysed program
intranasal foralumab (TZLS-401 / NI-0401) Non-active secondary progressive multiple sclerosis (na-SPMS) 2026-09-15 → 2026-11-30 confirmed readout window (expected period) Cleared (data check passed)
Miss
35% [20–52]
$0.30–$0.55 $1.80–$3.00
$1.12+11.6% modelled estimate

-18.0% to +45.2% compared with the current price, across our 20–52% range of probabilities. We cannot tell yet whether it is above or below the current price.

CGEM Cullinan Therapeutics, Inc. 1 analysed program
Zipalertinib (CLN-081 / TAS-6417) Previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer carrying an EGFR exon 20 insertion mutation (first line) 2026-10-01 → 2027-03-31 confirmed readout window (expected period) Cleared (data check passed)
Positive
78% [65–88]
$13.50–$16.25 $19.50–$24.00
$20.24+12.2% modelled estimate

+7.3% to +16.1% compared with the current price, across our 65–88% range of probabilities. We cannot tell yet whether it is above or below the current price.

DWTX Dogwood Therapeutics, Inc. 1 analysed program
Halneuron (purified tetrodotoxin) Chemotherapy-induced neuropathic pain (CINP) attributable to prior platinum and/or taxane chemotherapy 2026-10-01 → 2026-12-31 confirmed readout window (expected period) Cleared (data check passed)
Miss
38% [26–49]
$0.28–$1.28 $3.28–$9.50
$2.91+50.5% modelled estimate

+15.7% to +82.4% compared with the current price, across our 26–49% range of probabilities. We cannot tell yet whether it is above or below the current price.

GNLX Genelux Corporation 1 analysed program
Olvi-Vec (olvimulogene nanivacirepvec), also known as GL-ONC1 and GLV-1h68, an engineered oncolytic vaccinia virus, given intraperitoneally and followed by platinum-doublet chemotherapy plus bevacizumab Platinum-resistant or platinum-refractory, non-resectable high-grade serous, endometrioid or clear-cell ovarian, fallopian tube or primary peritoneal cancer, after at least three prior lines of systemic therapy including bevacizumab 2026-10-01 → 2027-04-30 confirmed readout window (expected period) Cleared (data check passed)
Uncertain
35% [20–55]
$0.45–$1.30 $6.00–$14.00
$4.07+49.6% modelled estimate

-0.7% to +116.7% compared with the current price, across our 20–55% range of probabilities. We cannot tell yet whether it is above or below the current price.

IVA Inventiva S.A. 1 analysed program
lanifibranor (IVA337) Non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis stage F2 or F3 2026-10-01 → 2026-12-31 confirmed readout window (expected period) Cleared (data check passed)
Positive
55% [40–70]
$1.00–$2.00 $7.00–$13.00
$6.18+30.9% modelled estimate

+3.8% to +57.8% compared with the current price, across our 40–70% range of probabilities. We cannot tell yet whether it is above or below the current price.

RAPP Rapport Therapeutics, Inc. 1 analysed program
RAP-219 Acute treatment of manic episodes, with or without mixed features, associated with bipolar I disorder, in adults aged 18-65 2026-10-01 → 2026-11-30 confirmed readout window (expected period) Cleared (data check passed)
Miss
35% [22–48]
$37.00–$45.00 $56.00–$68.00
$48.35-1.2% modelled estimate

-6.8% to +4.4% compared with the current price, across our 22–48% range of probabilities. We cannot tell yet whether it is above or below the current price.

IMMP Immutep Limited 1 analysed program
Eftilagimod alfa (efti, IMP321) with pembrolizumab and radiotherapy Resectable, non-metastatic, FNCLCC grade 2-3 soft tissue sarcoma of the extremities, girdles or superficial trunk, primary tumour larger than 5 cm or any locally recurrent tumour, given before surgery 2026-10-19 → 2026-10-19 confirmed readout window (expected period) Cleared (data check passed)
Positive
85% [72–92]
$2.30–$3.00 $3.05–$4.00
$3.39+6.1% modelled estimate

+2.5% to +8.0% compared with the current price, across our 72–92% range of probabilities. We cannot tell yet whether it is above or below the current price.

CMPX Compass Therapeutics, Inc. 1 analysed program
Tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody Second-line unresectable advanced, metastatic or recurrent biliary tract cancer 2026-10-23 → 2026-10-27 confirmed readout window (expected period) Cleared (data check passed)
Uncertain
45% [32–58]
$0.62–$0.84 $0.87–$1.15
$0.86-0.5% modelled estimate

-4.7% to +3.8% compared with the current price, across our 32–58% range of probabilities. We cannot tell yet whether it is above or below the current price.

ABOS Acumen Pharmaceuticals 1 analysed program
sabirnetug (ACU193) Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia, amyloid-confirmed) 2026-11-15 → 2027-01-31 confirmed readout window (expected period) Cleared (data check passed)
Miss
35% [25–48]
$0.55–$1.20 $4.50–$11.00
$3.28+43.9% modelled estimate

+13.8% to +83.1% compared with the current price, across our 25–48% range of probabilities. We cannot tell yet whether it is above or below the current price.

IMUX Immunic, Inc. 1 analysed program
vidofludimus calcium (IMU-838) Relapsing multiple sclerosis (relapsing-remitting and active secondary progressive) 2026-12-01 → 2027-03-31 confirmed readout window (expected period) Cleared (data check passed)
Positive
60% [50–70]
$2.40–$3.80 $17.00–$27.00
$14.44+2.4% modelled estimate

-11.0% to +15.8% compared with the current price, across our 50–70% range of probabilities. We cannot tell yet whether it is above or below the current price.

OLMA Olema Pharmaceuticals 1 analysed program
palazestrant (OP-1250) ER+/HER2- locally advanced or metastatic breast cancer, second and third line, after endocrine therapy plus a CDK4/6 inhibitor 2027-01-01 → 2027-06-30 confirmed readout window (expected period) Cleared (data check passed)
Uncertain
40% [30–52]
$4.50–$8.50 $15.50–$32.00
$13.40+28.5% modelled estimate

+11.9% to +48.3% compared with the current price, across our 30–52% range of probabilities. We cannot tell yet whether it is above or below the current price.

ZNTL Zentalis Pharmaceuticals 1 analysed program
azenosertib (ZN-c3) Cyclin E1-positive platinum-resistant ovarian cancer (PROC) 2027-01-01 → 2027-06-30 confirmed readout window (expected period) Cleared (data check passed)
Positive
55% [42–68]
$1.00–$2.30 $6.50–$10.00
$5.28+26.9% modelled estimate

+6.3% to +47.5% compared with the current price, across our 42–68% range of probabilities. We cannot tell yet whether it is above or below the current price.

Run-up priority ranking

A 0 to 100 score for each program, built from seven factors, and the test result on whether the score can be trusted yet

A "run-up" is a rise in a company's share price in the weeks before its trial result comes out. This table gives each analysed program a run-up priority score from 0 to 100 (formula v2.0.0, in lib/runup.mjs). The score is worked out fresh on every build. It does not read the list of locked predictions, so it is separate from the run-up calls already locked there. One part of the score, value_uplift, still uses the pre-2.0.0 method on this page. It needs an input called ratio_base that is not supplied yet. The 6.0.0 entry in CHANGELOG.md notes the same gap for the backtest. So the version label does not mean these numbers differ from 1.0.0's. The rows are ordered by when the readout window opens (the same earliest-date order as the table above), not by this score.

Score verdict: FAILING (in the test, the score did no better than chance at telling programs apart)

A backtest checks a score against past price moves. scripts/runup-backtest.mjs compared priority_score with real trading history for 141 of 144 rows (each row is one program on one past date). The measure is rho, a number from -1 to +1 that shows how well the score's ranking matches the ranking of the actual price rises. Higher is better, and 0 means no link at all. The pooled rho is -0.02. The pass mark was 0.3, and we set it before looking at any data. Unrounded, the pooled rho is -0.022. Computed within each past date, it averages -0.055 (range -0.25 to +0.335). A simple baseline that ranks by catalyst date scores 0.009, so the score is not better than that either. Only two of the seven drivers below vary in this data: how much is already priced in, and how easily the stock trades (part of "squeeze"). An earlier run (2026-08-06, formula 1.0.0) scored 0.257 and was judged INCONCLUSIVE. The rows below are ordered by the readout window and not by this score.

The seven drivers (the factors behind the score), left to right: UN Unmet need (how badly patients need a better treatment) (the same for every program today) VU Value uplift (how much a good result could add) (the same for every program today) OP Outcome probability (chance of a good result) (the same for every program today) DC Date confidence (how sure the date is) (the same for every program today) SQ Squeeze mechanics (how easily the price can jump) PI Priced-in-ness (how much is already in the price) FC Financing/clustering risk (need for cash, crowded events) (the same for every program today) Financing/clustering risk (FC) is red. For this one driver a high number means high risk, so it reads the other way.
Program Days to window (until the readout window opens) Attribution Score FAILING Drivers (0–100 each) Price trend
LGVN · Laromestrocel (Lomecel-B) Hypoplastic left heart syndrome (HLHS) — adjunct to stage-2 (Glenn) surgical palliation in infants Window opens 2026-08-12 Clean 6 /100 LGVN 1.39, -99.6% over the shown range
VALN · Shigella4V2 (S4V2) Prevention of shigellosis caused by Shigella sonnei and Shigella flexneri serotypes 2a, 3a and 6 Window opens 2026-08-13 Clean 6 /100 VALN 5.61, -78.9% over the shown range
MNOV · MN-001 (tipelukast) Hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) due to type 2 diabetes mellitus (T2DM) Window opens 2026-08-26 Indeterminate 6 /100 MNOV 1.42, -59.5% over the shown range
ARCT · ARCT-810 (LUNAR-OTC) Ornithine transcarbamylase (OTC) deficiency Window opens 2026-09-01 Clean 5 /100 ARCT 10.34, -78.5% over the shown range
CNTB · Rademikibart (CBP-201) Acute exacerbations of asthma with type 2 inflammation (blood eosinophils >=300 cells/uL), in adults and adolescents aged 12-75 Window opens 2026-09-01 Contaminated 6 /100 CNTB 0.91, -96.1% over the shown range
CNTB · Rademikibart (CBP-201) Acute exacerbations of COPD with type 2 inflammation (blood eosinophils >=300 cells/uL at the exacerbation), in adults aged 40-80, given as an add-on to standard of care Window opens 2026-09-01 Contaminated 6 /100 CNTB 0.91, -96.1% over the shown range
EVMN · EVO756 (oral MRGPRX2 antagonist) Moderate-to-severe atopic dermatitis Window opens 2026-09-01 Clean 6 /100 EVMN 5.17, -71.9% over the shown range
IRON · DISC-3405 (formerly MWTX-003) Polycythemia vera Window opens 2026-09-01 Indeterminate 5 /100 IRON 56.84, -53.4% over the shown range
RARE · GTX-102 (apazunersen) Angelman syndrome caused by full maternal UBE3A deletion, ages 4-17 Window opens 2026-09-01 Contaminated 6 /100 RARE 14.54, -83.6% over the shown range
TYRA · dabogratinib (TYRA-300) Low-grade, intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), FGFR3-altered Window opens 2026-09-01 Contaminated 6 /100 TYRA 18.52, -7.0% over the shown range
CUE · CUE-221 (formerly Ascendant-221, formerly UB-221) - humanised anti-IgE IgG1 monoclonal antibody Chronic spontaneous urticaria (long-lasting hives with no identifiable trigger), in patients inadequately controlled by H1-antihistamines Window opens 2026-09-15 Clean 5 /100 CUE 16.71, -94.7% over the shown range
TLSA · intranasal foralumab (TZLS-401 / NI-0401) Non-active secondary progressive multiple sclerosis (na-SPMS) Window opens 2026-09-15 Indeterminate 6 /100 TLSA 1.05, -46.4% over the shown range
CGEM · Zipalertinib (CLN-081 / TAS-6417) Previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer carrying an EGFR exon 20 insertion mutation (first line) Window opens 2026-10-01 Contaminated 5 /100 CGEM 12.93, -53.2% over the shown range
DWTX · Halneuron (purified tetrodotoxin) Chemotherapy-induced neuropathic pain (CINP) attributable to prior platinum and/or taxane chemotherapy Window opens 2026-10-01 Clean 6 /100 DWTX 1.22, -99.0% over the shown range
GNLX · Olvi-Vec (olvimulogene nanivacirepvec), also known as GL-ONC1 and GLV-1h68, an engineered oncolytic vaccinia virus, given intraperitoneally and followed by platinum-doublet chemotherapy plus bevacizumab Platinum-resistant or platinum-refractory, non-resectable high-grade serous, endometrioid or clear-cell ovarian, fallopian tube or primary peritoneal cancer, after at least three prior lines of systemic therapy including bevacizumab Window opens 2026-10-01 Indeterminate 6 /100 GNLX 2.42, -59.7% over the shown range
IVA · lanifibranor (IVA337) Non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis stage F2 or F3 Window opens 2026-10-01 Clean 6 /100 IVA 2.94, -73.8% over the shown range
RAPP · RAP-219 Acute treatment of manic episodes, with or without mixed features, associated with bipolar I disorder, in adults aged 18-65 Window opens 2026-10-01 Contaminated 6 /100 RAPP 27.57, +32.5% over the shown range
IMMP · Eftilagimod alfa (efti, IMP321) with pembrolizumab and radiotherapy Resectable, non-metastatic, FNCLCC grade 2-3 soft tissue sarcoma of the extremities, girdles or superficial trunk, primary tumour larger than 5 cm or any locally recurrent tumour, given before surgery Window opens 2026-10-19 Contaminated 24 /100 IMMP 3.20, -95.2% over the shown range
CMPX · Tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody Second-line unresectable advanced, metastatic or recurrent biliary tract cancer Window opens 2026-10-23 Contaminated 24 /100 CMPX 0.86, -78.2% over the shown range
ABOS · sabirnetug (ACU193) Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia, amyloid-confirmed) Window opens 2026-11-15 Clean 6 /100 ABOS 1.69, -88.7% over the shown range
IMUX · vidofludimus calcium (IMU-838) Relapsing multiple sclerosis (relapsing-remitting and active secondary progressive) Window opens 2026-12-01 Clean 6 /100 IMUX 6.97, -92.4% over the shown range
OLMA · palazestrant (OP-1250) ER+/HER2- locally advanced or metastatic breast cancer, second and third line, after endocrine therapy plus a CDK4/6 inhibitor Window opens 2027-01-01 Clean 6 /100 OLMA 6.58, -74.8% over the shown range
RARE · DTX301 (avalotcagene ontaparvovec) Late-onset ornithine transcarbamylase (OTC) deficiency, age 12 and over Window opens 2027-01-01 Contaminated 6 /100 RARE 14.54, -83.6% over the shown range
ZNTL · azenosertib (ZN-c3) Cyclin E1-positive platinum-resistant ovarian cancer (PROC) Window opens 2027-01-01 Clean 6 /100 ZNTL 2.13, -96.0% over the shown range
Driver detail table (all seven driver scores for each program)
Program UN VU OP DC SQ PI FC
LGVN/laromestrocel-hlhs 50 50 50 10 65 100 45
VALN/s4v2-shigellosis 50 50 50 10 65 88 45
MNOV/mn-001-nafld-hypertriglyceridemia 50 50 50 10 65 91 45
ARCT/arct-810-otc-deficiency 50 50 50 10 50 74 45
CNTB/rademikibart-acute-asthma-exacerbation 50 50 50 10 58 98 45
CNTB/rademikibart-acute-copd-exacerbation 50 50 50 10 58 98 45
EVMN/evo756-atopic-dermatitis 50 50 50 10 58 100 45
IRON/disc-3405-polycythemia-vera 50 50 50 10 43 72 45
RARE/gtx-102-angelman-syndrome 50 50 50 10 43 93 45
TYRA/dabogratinib-ir-nmibc 50 50 50 10 50 81 45
CUE/cue-221-csu 50 50 50 10 50 71 45
TLSA/foralumab-na-spms 50 50 50 10 65 78 45
CGEM/zipalertinib-1l-egfr-ex20ins-nsclc 50 50 50 10 50 62 45
DWTX/halneuron-cinp 50 50 50 10 65 99 45
GNLX/olvi-vec-platinum-resistant-ovarian 50 50 50 10 65 98 45
IVA/lanifibranor-mash 50 50 50 10 58 98 45
RAPP/rap-219-bipolar-mania 50 50 50 10 50 87 45
IMMP/efti-pembrolizumab-soft-tissue-sarcoma 50 50 50 40 65 100 45
CMPX/tovecimig-biliary-tract-cancer 50 50 50 40 58 99 45
ABOS/sabirnetug-alzheimers 50 50 50 10 65 91 45
IMUX/vidofludimus-relapsing-ms 50 50 50 10 58 85 45
OLMA/palazestrant-er-positive-mbc 50 50 50 10 50 100 45
RARE/dtx301-otc-deficiency 50 50 50 10 43 93 45
ZNTL/azenosertib-cyclin-e1-proc 50 50 50 10 58 84 45

Unmet need, value uplift and outcome probability all score a neutral 50. No run-up call has ever been locked, so there is no analyst judgement to read. Using today's real outcome probability would use knowledge from after the date being scored, so it is not used here. Date confidence is a stand-in based on whether BPIQ (the biotech data service we use) gives an exact day. It is low for every program. Financing/clustering risk uses a default value when no stored attribution or cash-runway call exists. Hover over a priced-in or squeeze number above to see how it was worked out.